Melanoma, version 2.2016 clinical practice guidelines in oncology Academic Article Article uri icon

Overview

MeSH Major

  • Analgesia
  • Pain Management
  • Phantom Limb
  • Spinal Cord Stimulation

abstract

  • This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.

authors

publication date

  • April 2016

Research

keywords

  • Academic Article

Identity

PubMed ID

  • 27059193

Additional Document Info

start page

  • 450

end page

  • 73

volume

  • 14

number

  • 4